Stable oncogenic silencing in vivo by programmable and targeted de novo DNA methylation in breast cancer

Oncogene

Volumn 34, Issue 43, 2015, Pages 5427-5435

  Stolzenburg, S ^a,b   Beltran, A S ^b   Swift Scanlan, T ^c   Rivenbark, A G ^b   Rashwan, R ^a   Blancafort, P ^a,b  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CHIMERIC PROTEIN; CLAUDIN 4; DNA; DOXYCYCLINE; KRUEPPEL ASSOCIATED PROTEIN 1; KRUPPEL LIKE FACTOR; MESSENGER RNA; RECOMBINANT ZINC FINGER PROTEIN 598 DNA METHYLTRANSFERASE 3A; TRANSCRIPTION FACTOR SOX2; TRANSCRIPTION FACTOR TWIST; UNCLASSIFIED DRUG; VIMENTIN; DNA (CYTOSINE 5) METHYLTRANSFERASE; DNA METHYLTRANSFERASE 3A; SOX2 PROTEIN, HUMAN; TRANSCRIPTION FACTOR SOX;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER INHIBITION; CELL DIVISION; CONTROLLED STUDY; DNA METHYLATION; DOWN REGULATION; DRUG EFFICACY; DRUG STABILITY; EPIGENETIC REPRESSION; EPIGENETICS; FEMALE; GENE SILENCING; GENE TARGETING; HUMAN; HUMAN CELL; IN VIVO STUDY; MCF 7 CELL LINE; MOUSE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DNA BINDING; PROTEIN PROTEIN INTERACTION; STABLE EXPRESSION; TUMOR XENOGRAFT; UPREGULATION; ZINC FINGER MOTIF; ANIMAL; BREAST TUMOR; GENE EXPRESSION; GENETIC EPIGENESIS; GENETICS; MCF-7 CELL LINE; METABOLISM; NUDE MOUSE; PHYSIOLOGY; TUMOR CELL LINE;

ANIMALS; BREAST NEOPLASMS; CELL DIVISION; CELL LINE, TUMOR; DNA (CYTOSINE-5-)-METHYLTRANSFERASE; DNA METHYLATION; DOWN-REGULATION; EPIGENESIS, GENETIC; FEMALE; GENE EXPRESSION; GENE SILENCING; HUMANS; MCF-7 CELLS; MICE; MICE, NUDE; PROMOTER REGIONS, GENETIC; SOXB1 TRANSCRIPTION FACTORS;

EID: 84945446360     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2014.470     Document Type: Article

References (39)

1. Kouzarides T. Chromatin modifications and their function. Cell 2007; 128: 693-705.
2. Beisel C, Paro R. Silencing chromatin: comparing modes and mechanisms. Nat Rev Genet 2011; 12: 123-135.
3. Lange UC, Schneider R. What an epigenome remembers. Bioessays 2010; 32: 659-668.
4. Sandoval J, Esteller M. Cancer epigenomics: beyond genomics. Curr Opin Genet Dev 2012; 22: 50-55.
5. The Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature 2012; 490: 61-70.
6. Stephens PJ, Tarpey PS, Davies H, Van Loo P, Greenman C, Wedge DC et al. The landscape of cancer genes and mutational processes in breast cancer. Nature 2012; 486: 400-404.
7. Curtis C, Shah SP, Chin SF, Turashvili G, Rueda OM, Dunning MJ et al. The genomic and transcriptomic architecture of 2, 000 breast tumours reveals novel subgroups. Nature 2012; 486: 346-352.
8. Boyer LA, Lee TI, Cole MF, Johnstone SE, Levine SS, Zucker JP et al. Core transcriptional regulatory circuitry in human embryonic stem cells. Cell 2005; 122: 947-956.
9. Brazel CY, Limke TL, Osborne JK, Miura T, Cai J, Pevny L et al. Sox2 expression defines a heterogeneous population of neurosphere-forming cells in the adult murine brain. Aging Cell 2005; 4: 197-207.
10. Sikorska M, Sandhu JK, Deb-Rinker P, Jezierski A, Leblanc J, Charlebois C et al. Epigenetic modifications of SOX2 enhancers, SRR1 and SRR2, correlate with in vitro neural differentiation. J Neurosci Res 2008; 86: 1680-1693.
11. Sussman RT, Stanek TJ, Esteso P, Gearhart JD, Knudsen KE, McMahon SB. The epigenetic modifier ubiquitin-specific protease 22 (USP22) regulates embryonic stem cell differentiation via transcriptional repression of sex-determining region Y-box 2 (SOX2). J Biol Chem 2013; 288: 24234-24246.
12. Schmitz M, Temme A, Senner V, Ebner R, Schwind S, Stevanovic S et al. Identification of SOX2 as a novel glioma-associated antigen and potential target for T cell-based immunotherapy. Br J Cancer 2007; 96: 1293-1301.
13. Bareiss PM, Paczulla A, Wang H, Schairer R, Wiehr S, Kohlhofer U et al. SOX2 expression associates with stem cell state in human ovarian carcinoma. Cancer Res 2013; 73: 5544-5555.
14. Bass AJ, Watanabe H, Mermel CH, Yu S, Perner S, Verhaak RG et al. SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. Nat Genet 2009; 41: 1238-1242.
15. Alonso MM, Diez-Valle R, Manterola L, Rubio A, Liu D, Cortes-Santiago N et al. Genetic and epigenetic modifications of Sox2 contribute to the invasive pheno-type of malignant gliomas. PLoS ONE 2011; 6: e26740.
16. Chen Y, Shi L, Zhang L, Li R, Liang J, Yu W et al. The molecular mechanism governing the oncogenic potential of SOX2 in breast cancer. J Biol Chem 2008; 283: 17969-17978.
17. Stolzenburg S, Rots MG, Beltran AS, Rivenbark AG, Yuan X, Qian H et al. Targeted silencing of the oncogenic transcription factor SOX2 in breast cancer. Nucleic Acids Res 2012; 40: 6725-6740.
18. Xiang R, Liao D, Cheng T, Zhou H, Shi Q, Chuang TS et al. Downregulation of transcription factor SOX2 in cancer stem cells suppresses growth and metastasis of lung cancer. Br J Cancer 2011; 104: 1410-1417.
19. Rivenbark AG, Stolzenburg S, Beltran AS, Yuan X, Rots MG, Strahl BD et al. Epigenetic reprogramming of cancer cells via targeted DNA methylation. Epigenetics 2012; 7: 350-360.
20. Siddique AN, Nunna S, Rajavelu A, Zhang Y, Jurkowska RZ, Reinhardt R et al. Targeted methylation and gene silencing of VEGF-A in human cells by using a designed Dnmt3a-Dnmt3L single-chain fusion protein with increased DNA methylation activity. J Mol Biol 2013; 425: 479-491.
21. Li F, Papworth M, Minczuk M, Rohde C, Zhang Y, Ragozin S et al. Chimeric DNA methyltransferases target DNA methylation to specific DNA sequences and repress expression of target genes. Nucleic Acids Res 2007; 35: 100-112.
22. de Groote ML, Verschure PJ, Rots MG. Epigenetic Editing: targeted rewriting of epigenetic marks to modulate expression of selected target genes. Nucleic Acids Res 2012; 40: 10596-10613.
23. Nunna S, Reinhardt R, Ragozin S, Jeltsch A. Targeted methylation of the epithelial cell adhesion molecule (EpCAM) promoter to silence its expression in ovarian cancer cells. PLoS ONE 2014; 9: e87703.
24. Chaikind B, Ostermeier M. Directed evolution of improved zinc finger methyl-transferases. PLoS ONE 2014; 9: e96931.
25. Blancafort P, Jin J, Frye S. Writing and rewriting the epigenetic code of cancer cells: from engineered proteins to small molecules. Mol Pharmacol 2013; 83: 563-576.
26. Stolzenburg S, Bilsland A, Keith WN, Rots MG. Modulation of gene expression using zinc finger-based artificial transcription factors. Methods Mol Biol 2010; 649: 117-132.
27. Choo Y, Sanchez-Garcia I, Klug A. In vivo repression by a site-specific DNA-binding protein designed against an oncogenic sequence. Nature 1994; 372: 642-645.
28. Boch J, Scholze H, Schornack S, Landgraf A, Hahn S, Kay S et al. Breaking the code of DNA binding specificity of TAL-type III effectors. Science 2009; 326: 1509-1512.
29. Bogdanove AJ, Voytas DF. TAL effectors: customizable proteins for DNA targeting. Science 2011; 333: 1843-1846.
30. Jinek M, Chylinski K, Fonfara I, Hauer M, Doudna JA, Charpentier E. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science 2012; 337: 816-821.
31. Wiedenheft B, Sternberg SH, Doudna JA. RNA-guided genetic silencing systems in bacteria and archaea. Nature 2012; 482: 331-338.
32. Konermann S, Brigham MD, Trevino A, Hsu PD, Heidenreich M, Le C et al. Optical control of mammalian endogenous transcription and epigenetic states. Nature 2013.
33. Fuks F, Burgers WA, Brehm A, Hughes-Davies L, Kouzarides T. DNA methyl-transferase Dnmt1 associates with histone deacetylase activity. Nat Gen 2000; 24: 88-91.
34. Esteve PO, Chin HG, Smallwood A, Feehery GR, Gangisetty O, Karpf AR et al. Direct interaction between DNMT1 and G9a coordinates DNA and histone methylation during replication. Genes Dev 2006; 20: 3089-3103.
35. Rodriguez J, Munoz M, Vives L, Frangou CG, Groudine M, Peinado MA. Bivalent domains enforce transcriptional memory of DNA methylated genes in cancer cells. Proc Natl Acad Sci USA 2008; 105: 19809-19814.
36. Hathaway NA, Bell O, Hodges C, Miller EL, Neel DS, Crabtree GR. Dynamics and memory of heterochromatin in living cells. Cell 2012; 149: 1447-1460.
37. Heyn H, Esteller M. DNA methylation profiling in the clinic: applications and challenges. Nat Rev Genet 2012; 13: 679-692.
38. Lara H, Wang Y, Beltran AS, Juarez-Moreno K, Yuan X, Kato S et al. Targeting serous epithelial ovarian cancer with designer zinc finger transcription factors. J Biol Chem 2012; 287: 29873-29886.
39. Beltran AS, Rivenbark AG, Richardson BT, Yuan X, Quian H, Hunt JP et al. Generation of tumor initiating cells by exogenous delivery of OCT4 Transcription Factor. Breast Cancer Res 2011; 13: R94.